Research Keyword: neuroimaging

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression

mycolabadmin

This research study is investigating how psilocybin, a compound from certain mushrooms, affects the brain in people with depression. The study involves 50 participants who will receive either psilocybin or a placebo, with their brain activity monitored using advanced imaging scans. Researchers will examine how psilocybin changes blood flow and network activity in brain regions involved in mood regulation, and whether these changes are linked to improvements in depression symptoms.

Read More »

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study

mycolabadmin

Researchers investigated whether psilocybin, a compound from certain mushrooms, could be safely used to treat memory problems in older adults with mild cognitive impairment. In this early-stage study, participants received either psilocybin or a placebo while researchers used brain imaging to measure changes in synaptic connections. The preliminary results suggest psilocybin was well-tolerated with manageable side effects like dizziness, and participants were able to complete the study without serious problems.

Read More »

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting

mycolabadmin

A research study examined how psilocybin experiences affect long-term mental health and well-being in healthy volunteers. Participants received two doses of psilocybin in controlled medical settings while undergoing brain imaging. The study found that psilocybin consistently produced positive, lasting improvements in mood, well-being, and spiritual outlook, regardless of whether people had used psychedelics before, their sex, or the specific imaging setting used.

Read More »

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

mycolabadmin

Psilocybin, the active compound in certain mushrooms, shows promise as a treatment for depression and anxiety in cancer patients, particularly those nearing end of life. Oregon legalized supervised psilocybin therapy in 2020, making it the first U.S. state to do so. While clinical research shows the treatment can rapidly reduce depression and improve quality of life, the actual rollout has faced challenges including regulatory hurdles, lack of professional standards, and unequal geographic access.

Read More »

Accelerated protein retention expansion microscopy using microwave radiation

mycolabadmin

Scientists have developed a faster way to examine brain tissue at extremely small scales using a combination of expansion microscopy and microwave radiation. Instead of waiting days for tissue samples to process, the new method cuts the time down to hours while maintaining the same quality of detailed images. The technique was successfully tested on tadpole and fruit fly brains, showing it could be useful for studying neural structures and potentially applied to studying brain diseases like Alzheimer’s.

Read More »
Scroll to Top